ORAL-NICOTINE-COMMISSION
Swedish authorities officially confirmed that the current level of smoking in Sweden has fallen to 5,6%. This makes Swedes the only European nation close to reaching the smoke-free goal set by the EU 18 years ahead of the 2040 target.
In an event organised by the Oral Nicotine Commission in Stockholm, participants took stock of Sweden’s incredible achievements and leadership in the race to end smoking. It is about to become the first country in the world to be defined as “smoke free”, representing a share of less than 5% of the population smoking.
Sweden’s smoking rates have shot down since the 1980s from 35% down to below 6% - a feat that is yet to be replicated by any other nation in the world. The next lowest smoking rate in Europe is double that of Sweden’s, with the EU average sitting somewhere around 23%, four times higher than in Sweden. The result is the lowest tobacco mortality rate in Europe.
A group of leading public health professionals, consumer advocates and harm reduction experts that met to celebrate the achievement on 30 November 2022 in Stockholm have reaffirmed their call to policymakers around the world to ensure that less harmful alternatives to smoking are available to support smokers to quit.
Commenting at the event, Dr. Delon Human, President of Health Diplomats and organiser of the event in Stockholm said: “If all smokers in the world, some 1.1 billion people, would switch to one of less harmful alternative smoke-free, nicotine-based products, it could prevent disease and save millions of lives worldwide. Sweden has found the fire-escape for smokers. We need to work together to repeat the Swedish experience globally to save lives.”
This incredible success story gave attendees the chance to better understand Sweden’s recipe to success, key to which is its openness to less harmful alternatives to smoking. Snus has been at the forefront of the reduction measures, but in recent years, nicotine pouches and e-cigarettes have become another valuable tool for Swedish smokers aiming to quit.
The progressive, pro harm-reduction Swedish model is clearly distinct from the policies proposed by international organisations in favour of tobacco control. At an EU level, harm reduction advocates have fought hard to have harm reduction recognised in the European Beating Cancer Plan. The WHO still refuses to acknowledge its value, despite the fact that harm reduction is explicitly recognised in the Framework Convention for Tobacco Control.
Commenting at the event, Professor Karl Fagerström said: “The upcoming Swedish EU presidency is a great opportunity to share their 5% success story to other EU countries. We hope that Sweden will be generous with sharing this know-how internationally.”
Speakers at the conference emphasised the need for sound evidence-based policy interventions in tobacco control. This translates to the broad adoption of tobacco harm reduction policies that support a journey to quitting smoking.
Ensuring that less harmful alternatives to smoking are affordable, accessible and affordable will be paramount to ensure that other countries can replicate Sweden’s success. This event is the start of much needed discussion of this topic.
The Oral Nicotine Commission is a global not-for-profit association that helps build the evidence base and raise awareness of Oral Nicotine among both governments, public health leaders and the public, thus countering negative, unfounded preconceptions and stereotypes. It addresses policy, science, consumer issues and relevant product innovations. Its views are independent of any brand or manufacturer and focuses on the individual and population health needs of adult smokers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005671/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top Performers Turn AI Vision Into Value8.12.2025 14:00:00 CET | Press release
Study reveals how the top 15% of companies are 2.5x more likely to post >10% revenue growth and over 3x more likely to achieve ≥15% profit margins from AI deployments NTT DATA, a global leader in AI, digital business and IT services, today released the 2026 Global AI Report: A playbook for AI leaders. The playbook is based on the company’s new benchmark research and reveals how “AI leaders” are separating from competitors through strategy and execution. The analysis is based on a survey of 2,567 senior executives across 35 countries and 15 industries. Only 15% of participating organizations qualified as “AI leaders,” defined by clear AI strategies, mature operating models and focused execution. These leaders report significantly higher revenue growth and profit margins than other organizations. “AI accountability now belongs in the boardroom and demands an enterprise-wide agenda,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Our research shows that a small group of AI leader
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies8.12.2025 14:00:00 CET | Press release
Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212 (212Pb) The established capability to receive and process high-activity 228Th, provides a key competitive advantage in scaling up 212Pb production to support the rapid advancement of 212Pb-ADVC001 (ADVC001) clinical development and the expanding pipeline The received 228Th will be processed into sources for our proprietary generator and installed in production systems first in Australia and subsequently in the US, as part of the planned expansion AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 14:00:00 CET | Press release
Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLLAdditional ASH data from investigational BTK degrader, BGB-16673, highlight potential first- and best-in-class activity with durable responses in heavily pretreated patients with CLL BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology,
Pink Changing Lives®: Mary Kay Builds 11th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings8.12.2025 14:00:00 CET | Press release
Each year, Mary Kay supports causes that enrich millions of women’s lives globally, including access to education Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious resources, and create opportunities that help women and their families thrive. Since 1996, the multi-faceted Pink Changing Lives® Program has donated over $230 million in monetary and in-kind donations to improve the lives of women and their families in communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208554750/en/ Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing p
IonQ Expands in EU With Slovakia’s First National Quantum Communication Network8.12.2025 13:05:00 CET | Press release
Partnering with the Slovak Academy of Sciences, IonQ bolsters national security and European quantum communications infrastructure IonQ (NYSE: IONQ), the world’s leading quantum company, through its subsidiary ID Quantique (IDQ), today announced the deployment of Slovakia’s first national quantum communication network. Developed in partnership with the Institute of Physics, Slovak Academy of Sciences (IPSAS), the new system features a resilient hybrid architecture designed to strengthen the country’s cybersecurity infrastructure and support Europe’s quantum digital programs. The Slovak Quantum Communication Infrastructure (skQCI) project represents a major milestone in Slovakia’s contribution to the European Quantum Communication Infrastructure (EuroQCI) initiative, which seeks to establish a secure quantum-resistant communication backbone covering all European Union (EU) member states and territories. By integrating quantum-safe technologies at a national scale, Slovakia will directly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
